Pharma view of my son
My view of my son
Apparently when pharmaceutical company executives contemplate the Autistic Disorder which limits the life of my son, and the lives of many who suffer from the limitations imposed by Autistic Disorder, they see Autistic Disorder Therapeutic Market Opportunities, as described in thepharmaletter:
"The autism spectrum disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 7.5% over the next eight years to reach $5.5 billion by 2018, finds GlobalData’s new report titled Autistic Disorder Therapeutics.
This market growth is primarily attributed to the high prevalence (0.6% to 1%) and prevalence growth rate (10-17%) of ASD in the US and in certain European countries. Co-morbidities such as anxiety, epilepsy and depression associated with ASD also contribute to the growth of the ASD therapeutics market.
Preference for educational/behavioral therapy over medication
GlobalData’s analysis suggests that educational/behavioral therapies such as Applied Behavioral Analysis (ABA) through environmental changes and behavior modification are the preferred treatment options for ASD patients. There are two approved drugs available on the market for the treatment of irritability associated with autistic disorder; while off-label drugs are prescribed to provide symptomatic relief only.
Therefore, behavioral therapy is the preferred treatment option over drug therapy. However, drug treatment is still required in certain physiatric disorders and with certain challenging behavior associated with ASD. Approximately 50%-70% people are prescribed drug therapy as behavior therapies alone are not always sufficient for managing the disease."
Translating from Pharma Speak ($$$) into one of the known human languages (English): pharmaceutical corporate profits should continue to rise with increases in Autism Spectrum Disorder diagnoses. Not to worry about ABA and other behavioral interventions ... "preferred" options ... depriving "pharma" (their expression not mine) of profits.
I hope pharma will forgive me. When I see my son I do not see an Autistic Disorder Market Opportunity I see a wonderful and amazing boy who has enriched my life in a way not contemplated in pharma newsletters. I don't see $$$ when I see my son. I see his amazing smile, his laughter, the joy he brings us each day.